Desvenlafaxine extended-release tablet for adult major depressive disorder

Desvenlafaxine is an extended-release oral tablet used for the treatment of major depressive disorder (MDD) in adults. It acts as a serotonin and norepinephrine reuptake inhibitor (SNRI) to help balance neurotransmitters in the brain. Available in 25 mg, 50 mg, and 100 mg doses, desvenlafaxine requires once-daily administration and careful monitoring for side effects and safety concerns.

Desvenlafaxine is approved for the treatment of major depressive disorder (MDD) in adult patients. It is not indicated for use in pediatric patients.

Desvenlafaxine succinate

Desvenlafaxine works by inhibiting the reuptake of the neurotransmitters serotonin and norepinephrine in the brain, which helps improve mood and symptoms of depression. It is the major active metabolite of venlafaxine, exerting its antidepressant effects by increasing the availability of these chemicals in nerve cells.

Recommended Adult Dosage

• 50 mg once daily, with or without food, is the starting and therapeutic dose.
• Tablets must be swallowed whole and not divided, crushed, chewed, or dissolved.
• The dose should be taken at approximately the same time each day.

Dosage Adjustments

• Renal impairment: For moderate impairment (creatinine clearance 30-50 mL/min), maximum dose is 50 mg daily.
• For severe impairment (creatinine clearance 15-29 mL/min) or end-stage renal disease, the dose should be reduced to 25 mg daily or 50 mg every other day. Do not give supplemental doses after dialysis.
• Hepatic impairment: In moderate to severe cases (Child-Pugh score 7-15), do not exceed 100 mg daily.
• Dose reduction: A 25 mg dose is used to taper patients gradually off therapy to minimize discontinuation symptoms.

Discontinuation

Gradual dose reduction is recommended whenever possible to reduce the risk of withdrawal effects. In some patients, tapering may need to occur over several months.

Special Instructions

• Allow at least 14 days after stopping an MAOI before starting desvenlafaxine and at least 7 days after stopping desvenlafaxine before starting an MAOI.
• Do not start desvenlafaxine with linezolid or intravenous methylene blue due to serotonin syndrome risk; if unavoidable, stop desvenlafaxine before these treatments.

• Known hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride, or any excipients in this formulation, including angioedema.
• Concomitant use with monoamine oxidase inhibitors (MAOIs) intended to treat psychiatric disorders or within 7 days of stopping desvenlafaxine.
• Use of desvenlafaxine within 14 days of stopping an MAOI.
• Starting desvenlafaxine in patients currently being treated with linezolid or intravenous methylene blue.

Boxed Warning: Suicidal Thoughts and Behaviors

Antidepressants including desvenlafaxine increase the risk of suicidal thoughts and behaviors in children, adolescents, and young adults (up to age 24) particularly during the initial treatment period. No increased risk was seen in patients over 24 years; risk decreased in patients aged 65 and older.

Close monitoring for worsening depression, suicidality, or unusual behavior is essential, especially early in treatment or at dose changes. Families and caregivers should be informed to observe for symptoms and report promptly.

Serotonin Syndrome

There is a potentially life-threatening risk of serotonin syndrome with desvenlafaxine, alone or combined with other serotonergic agents (including SSRIs, SNRIs, triptans, opioids, lithium, tramadol, and others). Symptoms may include mental status changes, autonomic instability, neuromuscular abnormalities, seizures, and gastrointestinal symptoms.

Discontinue desvenlafaxine and other serotonergic drugs if serotonin syndrome occurs and provide supportive treatment.

Blood Pressure Elevation

Hypertension may develop or worsen. Control blood pressure before starting desvenlafaxine and monitor regularly. Consider dose reduction or discontinuation if sustained blood pressure elevation occurs.

Bleeding Risk

Concomitant use with aspirin, NSAIDs, anticoagulants, or other drugs affecting hemostasis increases bleeding risk. Monitor carefully for bleeding signs.

Angle Closure Glaucoma Risk

Antidepressants can cause pupillary dilation that may precipitate an angle closure attack in patients with narrow angles. Avoid use in patients with untreated anatomically narrow angles.

Activation of Mania/Hypomania

Use cautiously in patients with bipolar disorder or a history/family history of mania. Symptoms of mania or hypomania have been reported.

Discontinuation Syndrome

Abrupt cessation can cause withdrawal symptoms such as nausea, irritability, dizziness, sensory disturbances, anxiety, and seizures. Taper gradually whenever possible.

Seizure

Desvenlafaxine should be used cautiously in patients with seizure disorders.

Hyponatremia

May occur due to SIADH, especially in elderly or patients using diuretics. Monitor sodium levels and discontinue if symptomatic hyponatremia develops.

Interstitial Lung Disease and Eosinophilic Pneumonia

Rare cases have been reported; evaluate patients with new respiratory symptoms promptly and consider discontinuation.

Sexual Dysfunction

Can cause sexual side effects including decreased libido, delayed ejaculation, anorgasmia, and erectile dysfunction. Patients should be counseled and monitored.

Common Adverse Reactions (≥5% incidence and at least twice placebo rate)

• Nausea
• Dizziness
• Insomnia
• Hyperhidrosis (excessive sweating)
• Constipation
• Somnolence (sleepiness)
• Decreased appetite
• Anxiety
• Specific male sexual dysfunctions (e.g., ejaculation disorders)

Other Noted Reactions (

• Tachycardia
• Asthenia (weakness)
• Weight increase
• Elevated liver function tests
• Blood prolactin increase
• Musculoskeletal stiffness
• Syncope, convulsions, dystonia
• Depersonalization, bruxism
• Urinary retention
• Skin reactions: rash, alopecia, photosensitivity, angioedema

Serious postmarketing reports (rare)

• Stevens-Johnson syndrome
• Acute pancreatitis
• Takotsubo cardiomyopathy
• Anosmia and hyposmia

Contraindicated Interactions

• Monoamine Oxidase Inhibitors (MAOIs): Use with MAOIs is contraindicated due to serotonin syndrome risk. This includes linezolid and intravenous methylene blue.

Significant Interactions Requiring Caution and Monitoring

• Other serotonergic drugs: Increased risk of serotonin syndrome when combined with SSRIs, other SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. John's Wort.
• Drugs that affect bleeding: Use with aspirin, NSAIDs, warfarin, or anticoagulants may increase bleeding risk; monitor closely.
• CYP2D6 substrates: Desvenlafaxine may increase plasma levels of drugs metabolized by CYP2D6 (e.g., desipramine, atomoxetine, metoprolol). Dose adjustment may be required at higher desvenlafaxine doses (400 mg).

Other Notes

• No dosage adjustment needed for drugs metabolized by CYP3A4 when used with desvenlafaxine.
• False-positive urine drug screens for PCP and amphetamine can occur due to desvenlafaxine; confirmatory testing recommended.
• Alcohol may exacerbate CNS effects and should be avoided.

No specific antidote exists for desvenlafaxine overdose. Management should consider the possibility of multiple drug involvement. Contact Poison Control Center at 1-800-222-1222 for recommendations.